This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Über die Bedeutung von Leitlinien wird an anderer Stelle in diesem Buch berichtet (▶ Kap. 7).
Literatur
Weiterführende Literatur:
House of Commons Health Committee (2005) The influence of the pharmaceutical industry. Fourth report of session 2004–05, Volume I. Ordered by The House of Commons, London
ISDB and WHO (2005) Starting or strengthening a drug bulletin. International Society of Drug Bulletins and World Health Organization, Geneva. Erhältlich unter: www.isdbweb.org
Lo B, Field M (Hrsg) (2009) Conflict of interest in medical research, education and practice. National Academies Press, Washington DC
Spielmans GI, Perry P (2010) From evidence-based medicine to marketing-based medicine. Bioeth Inq 7: 13–29
Spurling GK, Mansfield PR et al (2010) Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med 7: e1000352
Andere zitierte Literatur:
at (2008) Zertifizierte Fortbildung: Werbeplattform statt Lehrangebot. arznei-telegramm 39: 81-–82
Becker A, Dörter F et al (2011) The association between a journal’s source of revenue and the drug recommendations made in the articles it publishes. Can Med Ass J; 183: 544–548
Brody H, Light DW (2011) The inverse benefit law: how drug marketing undermines patient safety and public health. Am J Public Health 101: 399–404
BUKO Pharma-Kampagne (2010) Schöne neue Pharmawelt. Pharma-Brief Spezial 1/2010
Caplovitz A (2006) Turning medicine into snake oil: how pharmaceutical marketers put patients at risk. NJPIRG Law & Policy Center, US http://www.njpirg.org/health-care/campaign-for-safe-drugs. Zugegriffen: 8. April 2011
Chimonas S, Frosch Z, Rothman DJ (2011) From disclosure to transparency: the use of company payment data. Arch Intern Med 171: 81–86
DesignWrite (1997) Strategic competitive intelligence on the HRT market: a source document. Speakers Bureau Meeting (Internet) Drug Industry Document Archive, San Francisco. http://dida.library.ucsf.edu/tid/jtb37b10. Zugegriffen: 13. April 2011
Ewart R, Lausen H, Millian N (2009) Undisclosed changes in outcomes in randomized controlled trials: an observational study. Ann Fam Med 7: 542–546
Eyding D, Lelgemann M et al (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737 doi: 10.1136/bmj.c4737
Fugh-Berman AJ (2010) The haunting of medical journals: how ghostwriting sold “HRT”. PLoS Med 7: e1000335
Garattini L, Koleva D, Casadei G (2010) Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care 26: 330–333. doi:10.1017/S0266462310000322
Harris G (2010) Diabetes drug maker hid test data, files indicate. New York Times July 13, Das Dokument als Faksimile: http://documents.nytimes.com/avandia-and-its-risks?ref=policy#document/p8/a3
IQWiG (2010) Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht Auftrag A05-01. Stand 18. 2. 2010
Katz D, Caplan AL, Merz JF (2010) All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth; 10 (10): 11-17, DOI: 10.1080/15265161.2010.519226
Kirsch I, Deacon BJ et al (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45. doi:10.1371/journal.pmed.0050045
Koneczny N, Butzlaff M (2006) How to change physicians’ practice? Das Knowledge- Performance- Gap im Fokus der Versorgungsforschung. Z. Evid. Fortbild. Qual. Gesundh. Wesen 100: 23–28
Lieb K, Klemperer D, Koch K et al (2011) Interessenkonflikte in der Medizin. Mit Transparenz Vertrauen stärken. Dtsch Arztebl 108 (6): A256–260
Lundh A, Barbateskovic M et al (2010) Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue – cohort study. PLoS Med 7: e1000354
McGauran N, Wieseler B et al (2010) Reporting bias in medical research – a narrative review. Trials 11: 37
Mello MM, Studdert DM, Brennan TA (2009) Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med 360: 1557-1566. doi: 10.1056/NEJMhle0807695
Newman M (2010) Bitter pills for drug companies. BMJ 341: 632–633 doi: 10.1136/bmj.c5095
Pharma-Brief (2009) Elsevier Verlag kämpft um seinen Ruf. Pharma-Brief 8/2009: 2
Prescrire International (2006) 15 years of monitoring and one simple conclusion: don’t expect sales representatives to help improve healthcare quality. Prescrire Int. 15: 154–159
Pro Publica (2011) Dollars for docs, http://projects.propublica.org/docdollars/. Zugegriffen: 8. April 2011
Ross JS, Hill KP et al (2008) Guest authorship and ghostwriting in publications related to Rofecoxib. JAMA 299: 1800–1812
Schneider N, Lückmann SL (2008) Pharmasponsoring in der ärztlichen Fort- und Weiterbildung. Z Allg Med 84: 516–524
Sismondo S, Doucet M (2010) Publication ethics and the ghost management of medical publication. Bioethics 24: 273–283 doi:10.1111/j.1467-8519.2008.01702.x
Smith R (2010) Richard Smith on editors’ conflict of interest. BMJ blog 2. Nov 2010
Schott G, Pachl H et al (2010a) The financing of drug trials by pharmaceutical companies and Its consequences: part 1. A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials, Dtsch Arztebl Int 2010; 107(16): 279–85 doi: 10.3238/arztebl.2010.0279
Schott G, Pachl H et al (2010b) The financing of drug trials by pharmaceutical companies and Its consequences: Part 2. A qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int; 107(17): 295–301 doi: 10.3238/arztebl.2010.0295
Transparency International (Deutschland) (2008) Transparenzmängel, Korruption und Betrug im deutschen Gesundheitswesen – Kontrolle und Prävention als gesellschaftliche Aufgabe. Grundsatzpapier von Transparency Deutschland. Stand Juni 2008, 5. Auflage
Turner EH, Mathews AM et al (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252–60
US Library of Medicine (2011) Fact Sheet Medline http://www.nlm.nih.gov/pubs/factsheets/medline.html. Zugegriffen 10. April 2011
WHO and HAI (2010) Understanding and responding to pharmaceutical promotion. WHO/Health Action International, Geneva/Amsterdam. www.haiweb.org/03_other.htm
WHO Europe (1985) Independent drug bulletins. Report of an international WHO meeting on drug information. WHO Regional Office for Europe, Madrid Copenhagen
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schaaber, J., Kochen, M., Müller-Oerlinghausen, B., Niebling, W. (2011). Warum unabhängige Arzneimittelzeitschriften und Fortbildungsveranstaltungen wichtig sind. In: Lieb, K., Klemperer, D., Ludwig, WD. (eds) Interessenkonflikte in der Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19842-7_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-19842-7_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-19841-0
Online ISBN: 978-3-642-19842-7
eBook Packages: Medicine (German Language)